EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 56 / No 3 (September 2024) J Extra Corpor Technol, 56 3 (2024) 136-144 References
Open Access
Review
Issue
J Extra Corpor Technol
Volume 56, Number 3, September 2024
Page(s) 136 - 144
DOI https://doi.org/10.1051/ject/2024015
Published online 20 September 2024
  1. Weiss RJ, Esko JD, Tor Y. Targeting heparin and heparan sulfate protein interactions. Org Biomol Chem. 2017;27:5656–5668. [CrossRef] [PubMed] [Google Scholar]
  2. Mushunje A, Zhou A, Carrell RW, Huntington JA. Heparin-induced substrate behavior of antithrombin Cambridge II. Blood. 2003;102(12):4028–4034. [CrossRef] [PubMed] [Google Scholar]
  3. Rosin MW, Holt D. Heparin dose and postoperative bleeding in patients undergoing cardiopulmonary bypass. J Extra Corpor Technol. 2013;45(4):228–234. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  4. Chen Y, Phoon PHY, Hwang NC. Heparin resistance during cardiopulmonary bypass in adult cardiac surgery. J Cardiothorac Vasc Anesth. 2022;36(11):4150–4160. [CrossRef] [PubMed] [Google Scholar]
  5. Finley A, Greenberg CS. Heparin sensitivity and resistance. Anesth Analg. 2013;116(6):1210–1222. [CrossRef] [PubMed] [Google Scholar]
  6. Staples MH, Dunton RF, Karlson KJ, Leonardi HK, Berger RL. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg. 1994;57(5):1211–1216. [CrossRef] [PubMed] [Google Scholar]
  7. Chan T, Hwang NC, Lim CH. A statistical analysis of factors predisposing patients to heparin resistance. Perfusion. 2006;21(2):99–103. [CrossRef] [PubMed] [Google Scholar]
  8. Lemmer J, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2002;123(2):213–217. [CrossRef] [PubMed] [Google Scholar]
  9. Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017;129(21):2864–2872. [CrossRef] [PubMed] [Google Scholar]
  10. Krzych ŁJ, Nowacka E, Knapik P. Małopłytkowość poheparynowa. Anestezjol Intens Ter. 2015;47(1):63–76. [Google Scholar]
  11. Franchini M. Heparin-induced thrombocytopenia: an update. Thromb J. 2005;3:14. [CrossRef] [PubMed] [Google Scholar]
  12. Nazy I, Clare R, Staibano P, Warkentin TE, Larché M, Moore JC, et al. Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2018;16(7):1402–1412. [CrossRef] [PubMed] [Google Scholar]
  13. Savioli F, Claro M, Da Silva Ramos FJ, Pastore L. Factor VIII, fibrinogen and heparin resistance in COVID-19 patients with thromboembolism: how should we manage the anticoagulation therapy? Clin Appl Thromb Hemost. 2022;28:107602962210876. [CrossRef] [Google Scholar]
  14. Durrani J, Malik F, Ali N, Jafri SIM. To be or not to be a case of heparin resistance. J Community Hosp Intern Med Perspect. 2018;8(3):145–148. [CrossRef] [PubMed] [Google Scholar]
  15. Bock S, Marrinan JA, Radziejewska E. Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site. Biochemistry. 1988;27(16):6171–6178. [CrossRef] [PubMed] [Google Scholar]
  16. Hultin MB, McKay J, Abildgaard U, Antithrombin Oslo: Type Ib classification of the first reported antithrombin-deficient family, with a review of hereditary antithrombin variants. Thromb Haemost. 1988;59(3):468–473. [CrossRef] [PubMed] [Google Scholar]
  17. Mitchell L, Hoogendoorn H, Giles A, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L’Asparaginase-induced antithrombin III deficiency. Blood. 1994;83(2):386–391. [CrossRef] [PubMed] [Google Scholar]
  18. Levy JH, Connors JM. Heparin resistance – clinical perspectives and management strategies. New Engl J Med. 2021;385(9):826–832. [CrossRef] [PubMed] [Google Scholar]
  19. Bharadwaj J, Jayaraman C, Shrivastava R. Heparin resistance. Lab Hematol. 2003;9(3):125–131. [PubMed] [Google Scholar]
  20. Muedra V, Bonanad S, Gómez M, Villalonga V, Sánchez F, Llopis JE. Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass. Perfusion. 2011;26(6):487–495. [CrossRef] [PubMed] [Google Scholar]
  21. Warnock LB, Huang D. Heparin. Jul 10. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2024. PMID: 30855835. [Google Scholar]
  22. Edwards JK, Sniecinski RM, Scott KJ. Non-antithrombin-mediated heparin resistance during cardiac surgery: two case reports. AA Pract. 2019;13(6):211–214. [CrossRef] [Google Scholar]
  23. Knapik P, Cieśla D, Przybylski R, Knapik T. The influence of heparin resistance on postoperative complications in patients undergoing coronary surgery. Med Sci Monit. 2012;18(2):CR105–CR111. [CrossRef] [PubMed] [Google Scholar]
  24. Sniecinski RM, Bennett-Guerrero E, Shore-Lesserson L. Anticoagulation management and heparin resistance during cardiopulmonary bypass: A survey of Society of Cardiovascular Anesthesiologists members. Anesth Analg. 2019;129(2):e41–e44. [CrossRef] [PubMed] [Google Scholar]
  25. Avidan MS, Levy JH, van Aken H, Feneck RO, Latimer RD, Ott E, et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005;130:107–113. [CrossRef] [PubMed] [Google Scholar]
  26. Stammers AH, Francis SG, Miller RM, Nostro A, Tesdahl EA, Mongero LB. Application of goal-directed therapy for the use of concentrated antithrombin for heparin resistance during cardiac surgery. Perfusion. 2020;36(2):171–182. [Google Scholar]
  27. Puis L, Milojevic M, Boer C, De Somer FMJJ, Gudbjartsson T, van den Goor J, et al. EACTS/EACTA/EBCP Committee Reviewers. 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. Interact Cardiovasc Thorac Surg. 2020;30(2):161–202. [PubMed] [Google Scholar]
  28. Tibi P, McClure RS, Huang J, Baker RA, Fitzgerald D, Mazer CD, et al. STS/SCA/AMSECT/SABM update to the clinical practice guidelines on patient blood management. Ann Thorac Surg. 2021;112(3):981–1004. [CrossRef] [PubMed] [Google Scholar]
  29. Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia. 2008;14(6):1229–1239. [CrossRef] [PubMed] [Google Scholar]
  30. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg. 1975;69(5):674–684. [CrossRef] [PubMed] [Google Scholar]
  31. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg. 1978;26(3):231–240. [CrossRef] [PubMed] [Google Scholar]
  32. Metz S, Keats AS. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding. Ann Thorac Surg. 1990;49(3):440–444. [CrossRef] [PubMed] [Google Scholar]
  33. Jung HJ, Kim JB, Im KS, Oh SH, Lee JM. Heparin resistance during cardiopulmonary bypass. J Cardiovasc Med. 2009;10(12):940–941. [CrossRef] [PubMed] [Google Scholar]
  34. Kearon C, Akl EA, Ornelas J, Blaivas AJ, Jiménez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease. Chest. 2016;149(2):315–352. [CrossRef] [PubMed] [Google Scholar]
  35. Levy JH, Sniecinski RM, Rocca B, Ghadimi K, Douketis JD, Frère C, et al. Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis. J Thromb Haemost. 2023;21(12):3649–3657. [CrossRef] [PubMed] [Google Scholar]
  36. García D, Baglin T, Weitz JI, Samama M. Parenteral anticoagulants. Chest. 2012;141(2):e24S–e43S. [CrossRef] [PubMed] [Google Scholar]
  37. Kanbak M. The treatment of heparin resistance with antithrombin III in cardiac surgery. Can J Anaesth. 1999;46(6):581–585. [CrossRef] [PubMed] [Google Scholar]
  38. Mahmood S, Bilal H, Zaman M, Tang A. Is a fully heparin-bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit? Interact Cardiovasc Thorac Surg. 2012;14(4):406–414. [CrossRef] [PubMed] [Google Scholar]
  39. Kitchen S. Problems in laboratory monitoring of heparin dosage. Br J Haematol. 2000;111(2):397–406. [CrossRef] [PubMed] [Google Scholar]
  40. McMichael ABV, Ryerson L, Ratano D, Fan E, Faraoni D, Annich GM. 2021 ELSO adult and pediatric anticoagulation guidelines. ASAIO J. 2022;68(3):303–310. [CrossRef] [PubMed] [Google Scholar]
  41. Dietrich W, Spannagl M, Schramm W, Vogt W, Barankay A, Richter J. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. The J Thorac Cardiovasc Surg. 1991;102(4):505–514. [CrossRef] [Google Scholar]
  42. Ranucci M, Frigiola A, Menicanti L, Cazzaniga A, Soro G, Isgrò G. Risk factors for fatal myocardial infarction after coronary bypass graft surgery. Eur J Anaesthesiol. 2001;18(5):322–329. [CrossRef] [PubMed] [Google Scholar]
  43. Saydam O, Atay M, Şerefli D, Doğancı S, Kumabasar U, Yılmaz M, et al. Preoperative low-molecular-weight heparin prophylaxis associated with increased heparin resistance frequency in on-pump coronary artery bypass graft surgery. Cardiol Res Pract. 2019;2019:1–5. [CrossRef] [Google Scholar]
  44. Kimura Y, Okahara S, Abo K, Koyama Y, Kuriyama M, Ono K, et al. Infective endocarditis is a risk factor for heparin resistance in adult cardiovascular surgical procedures: a retrospective study. J Cardiothorac Vasc Anesth. 2021;35(12):3568–3573. [CrossRef] [PubMed] [Google Scholar]
  45. Sniecinski R, Szlam F, Chen EP, Bader SO, Levy JH, Tanaka KA. Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass. Anesth Analg. 2008;106(3):713–718. [CrossRef] [PubMed] [Google Scholar]
  46. Boysan E, Cırcı R, Beyazal OF, Şener E. Bivalirudin for cardiopulmonary bypass in a patient with heparin allergy. J Cardiothorac Surg. 2023;18(1):258. [CrossRef] [PubMed] [Google Scholar]
  47. Nikolaidis N, Velissaris T, Ohri SK. Bivalirudin anticoagulation for cardiopulmonary bypass: an unusual case. Tex Heart Inst J. 2007;34(1):115–118. [PubMed] [Google Scholar]
  48. Gosselin R, Douxfils J. Ecarin based coagulation testing. Am J Hematol. 2020;95(7):863–869. [CrossRef] [PubMed] [Google Scholar]
  49. Van Cott EM, Roberts AJ, Dager WE. Laboratory monitoring of parenteral direct thrombin inhibitors. Semin Thromb Hemost. 2017;43(3):270–276. [CrossRef] [PubMed] [Google Scholar]
  50. Häfner G, Roser M, Nauck M. Methods for the monitoring of direct thrombin inhibitors. Semin Thromb Hemost. 2002;28(5):425–430. [CrossRef] [PubMed] [Google Scholar]
  51. Boinot C, Lanquetot H, Macchi L, Charriëre JM, Menu P. Circulation extracorporelle sous lépirudine (Refludan®) dans un contexte de thrombopénie induite par l’héparine. Ann Fr Anesth Reanim. 2003;22(7):635–638. [CrossRef] [PubMed] [Google Scholar]
  52. Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, et al. Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with Heparin-Induced thrombocytopenia. Circulation. 1999;99(1):73–80. [CrossRef] [PubMed] [Google Scholar]
  53. Zucker MB, Koster A, Prats J, LaDuca FM. Sensitivity of a modified ACT test to levels of bivalirudin used during cardiac surgery. J Extra Corp Technol. 2005;37(4):364–368. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  54. Jabr K, Johnson JH, McDonald MH, Walsh DL, Martin WD, Johnson AC, Pickett JM, Shantha-Martin U. Plasma-modified ACT can be used to monitor bivalirudin (Angiomax) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia. J Extra Corpor Technology. 2004;36(2):174–177. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  55. Murase M, Usui A, Tomita Y, Maeda M, Koyama T, Abe T. Nafamostat mesilate reduces blood loss during open heart surgery. Circulation. 1993;88(5 Pt 2):II432–II436. [PubMed] [Google Scholar]
  56. Kikura M, Tanaka K, Hiraiwa T, Tanaka K. Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2012;26(2):239–244. [CrossRef] [PubMed] [Google Scholar]
  57. Sakamoto T, Hiroya K, Miyahara S, Inoue T, Izawa N, Gotake Y, et al. Efficacy of nafamostat mesilate as anticoagulation during cardiopulmonary bypass for early surgery in patients with active infective endocarditis complicated by stroke. J Heart Valve Dis. 2014;23(6):744–745. [PubMed] [Google Scholar]
  58. Kaminishi Y, Hiramatsu Y, Watanabe Y, Yoshimura Y, Sakakibara Y. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass. Ann Thorac Surg. 2004;77(2):644–650. [CrossRef] [PubMed] [Google Scholar]
  59. Levy JH, Connors JM. Heparin resistance – clinical perspectives and management strategies. New Eng J Med. 2021;385(9):826–832. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.